Tatyana I. Meshcheryakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tatyana I. Meshcheryakova has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Tatyana V. Kozhanova
Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children; Pirogov Russian National Research Medical University
10 shared publications - Nikolay N. Zavadenko
Pirogov Russian National Research Medical University
7 shared publications - Светлана Сергеевна Жилина
Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children; Pirogov Russian National Research Medical University
7 shared publications - Krapivkin Alexey Igorevich
Pirogov Russian National Medical University; V.F. Voyno-Yasenetsky Scientific and Practical Center for Specialized Assistance for Children of the Department of Healthcare of Moscow
5 shared publications - Александр Андреевич Абрамов
Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children
5 shared publications S. S. Zhylina
V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children, Moscow Healthcare Department
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 18 (3) , 236-245
The first clinical case of adenylosuccinate lyase deficiency in Russia documented in a girl with severe psychomotor delay, epilepsy and homozygous variant in ADSL gene
Adenylosuccinate lyase deficiency is a rare autosomal recessive disorder of purine metabolism caused by mutations in ADSL gene. Here, we describe a 3-year-old girl who presented with severe psychomotor delay and early-onset seizures since birth. Phenotypic assessment revealed microcephaly and brain magnetic resonance imaging showed signs of subcortical subatrophy and periventricular leukopathy. Genetic analysis identified previously described homozygous mutation (c.1277G>A, p.R426H) in ADSL gene. Increased awareness of adenylosuccinate lyase deficiency among pediatricians, neonatologists, pediatric neurologists, and radiologists is key to early detection of the disease. To investigate the underlying cause, perform molecular diagnosis and treatment strategy decision-making in such patients, genetic testing by whole-exome or whole-genome sequencing is required.
- 31 October 2026
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 18 (3) , 236-245
Open AccessThe first clinical case of adenylosuccinate lyase deficiency in Russia documented in a girl with severe psychomotor delay, epilepsy and homozygous variant in ADSL gene
Adenylosuccinate lyase deficiency is a rare autosomal recessive disorder of purine metabolism caused by mutations in ADSL gene. Here, we describe a 3-year-old girl who presented with severe psychomotor delay and early-onset seizures since birth. Phenotypic assessment revealed microcephaly and brain magnetic resonance imaging showed signs of subcortical subatrophy and periventricular leukopathy. Genetic analysis identified previously described homozygous mutation (c.1277G>A, p.R426H) in ADSL gene. Increased awareness of adenylosuccinate lyase deficiency among pediatricians, neonatologists, pediatric neurologists, and radiologists is key to early detection of the disease. To investigate the underlying cause, perform molecular diagnosis and treatment strategy decision-making in such patients, genetic testing by whole-exome or whole-genome sequencing is required.
- 5 October 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (4) , 92-100
STXBP1-associated developmental and epileptic encephalopathy type 4
The increased frequency of testing has led to STXBP1 variants being identified as one of the variants associated with neurological disorders. We describe genotype-phenotype correlations of three patients with STXBP1-associated developmental and epileptic encephalopathy that we observed. Our observations confirmed that the onset of seizures in two patients in the neonatal period was similar to Ohtahara syndrome, while no seizures were recorded in one girl with severe psychoneurological deficit. The seizures required the use of three anticonvulsants, but severe cognitive and motor deficits persist as the child grows older. Conclusions. Patients with neonatal seizures resistant to AEDs and psychoneurological deficits should whole exome or whole genome sequencing to search STXBP1 variants.
- 5 October 2026
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (4) , 92-100
STXBP1-associated developmental and epileptic encephalopathy type 4
The increased frequency of testing has led to STXBP1 variants being identified as one of the variants associated with neurological disorders. We describe genotype-phenotype correlations of three patients with STXBP1-associated developmental and epileptic encephalopathy that we observed. Our observations confirmed that the onset of seizures in two patients in the neonatal period was similar to Ohtahara syndrome, while no seizures were recorded in one girl with severe psychoneurological deficit. The seizures required the use of three anticonvulsants, but severe cognitive and motor deficits persist as the child grows older. Conclusions. Patients with neonatal seizures resistant to AEDs and psychoneurological deficits should whole exome or whole genome sequencing to search STXBP1 variants.
- Open Access
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 31-40
Genetic screening algorithm for children with medulloblastoma: a scoring system for stratifying the risk of hereditary variants
Introduction . Medulloblastoma is the most common malignant central nervous system tumor in children, representing a molecularly heterogeneous group of neoplasms (SHH, WNT, Group 3, Group 4 subtypes). Germline mutations in predisposition genes (PTCH1, SUFU, TP53, APC, BRCA2, PALB2, ELP1, GPR161) are identified in 5–15 % of patients, predominantly in SHH and WNT subtypes. The purpose of the study – to develop a screening algorithm with a risk stratification scoring system for hereditary medulloblastoma variants to rationally select patients for genetic testing. Materials and methods . The study included a cohort of 26 patients with medulloblastoma aged 0 to 18 years who received chemotherapy in 2024–2025 at V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children. Molecular subgroup determination was performed using NanoString technology or DNA methylation profiling. Genetic counseling was provided to all patients. Germline mutations in DNA extracted from peripheral blood were analyzed in 11 patients using parallel sequencing (whole exome sequencing) and Sanger sequencing. Results . Molecular classification was performed in 20 patients: SHH – 38 %, WNT – 5 %, Group 3 – 24 %, Group 4 – 29 %. Genetic testing was conducted in 11 patients, with pathogenic germline variants identified in 6 (55 %): Gorlin syndrome (n = 2), Li–Fraumeni syndrome (n = 1), Turcot syndrome type 2 (n = 1), Fanconi anemia/PALB2 (n = 1), ELP1 mutation (n = 1). Hereditary forms were exclusively found in SHH/WNT subtypes (100 %). Patients with pathogenic variants scored ³ 4 points. No pathogenic variants were identified in Group 3 and Group 4 cases. Conclusions . Genetic counseling with testing should be considered a standard procedure in the management of patients with SHH- and WNT-subtype medulloblastomas. The developed scoring system enables detection of 90–95% of hereditary forms while testing only 30–40 % of patients, improving diagnostic efficiency and optimizing resource utilization.
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 31-40
Open AccessGenetic screening algorithm for children with medulloblastoma: a scoring system for stratifying the risk of hereditary variants
Introduction . Medulloblastoma is the most common malignant central nervous system tumor in children, representing a molecularly heterogeneous group of neoplasms (SHH, WNT, Group 3, Group 4 subtypes). Germline mutations in predisposition genes (PTCH1, SUFU, TP53, APC, BRCA2, PALB2, ELP1, GPR161) are identified in 5–15 % of patients, predominantly in SHH and WNT subtypes. The purpose of the study – to develop a screening algorithm with a risk stratification scoring system for hereditary medulloblastoma variants to rationally select patients for genetic testing. Materials and methods . The study included a cohort of 26 patients with medulloblastoma aged 0 to 18 years who received chemotherapy in 2024–2025 at V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children. Molecular subgroup determination was performed using NanoString technology or DNA methylation profiling. Genetic counseling was provided to all patients. Germline mutations in DNA extracted from peripheral blood were analyzed in 11 patients using parallel sequencing (whole exome sequencing) and Sanger sequencing. Results . Molecular classification was performed in 20 patients: SHH – 38 %, WNT – 5 %, Group 3 – 24 %, Group 4 – 29 %. Genetic testing was conducted in 11 patients, with pathogenic germline variants identified in 6 (55 %): Gorlin syndrome (n = 2), Li–Fraumeni syndrome (n = 1), Turcot syndrome type 2 (n = 1), Fanconi anemia/PALB2 (n = 1), ELP1 mutation (n = 1). Hereditary forms were exclusively found in SHH/WNT subtypes (100 %). Patients with pathogenic variants scored ³ 4 points. No pathogenic variants were identified in Group 3 and Group 4 cases. Conclusions . Genetic counseling with testing should be considered a standard procedure in the management of patients with SHH- and WNT-subtype medulloblastomas. The developed scoring system enables detection of 90–95% of hereditary forms while testing only 30–40 % of patients, improving diagnostic efficiency and optimizing resource utilization.
- Open Access
- 18 July 2025
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 17 (2) , 170-181
A novel X-linked immune-mediated actinopathy in a boy with anti-NMDA receptor encephalitis and variant in DOCK11 gene
Pediatric encephalitis is a group of diseases characterized by brain disease, fever, seizures, cerebrospinal fluid pleocytosis and neuroradiological changes. Dedicator of cytokinesis proteins (DOCK) family proteins are of primary importance in actin cytoskeleton regulation. DOCK11 plays a crucial role in human immune diseases. In this paper, we describe a clinical case of anti-N-methyl-D-aspartate receptor encephalitis in a boy with a hemizygous variant in DOCK11 gene. DOCK11 deficiency is a new X-linked immunerelated actinopathy leading to impaired cell division cycle 42 (CDC42) activity and signal transducer and activator of transcription 5 (STAT5) activation. It is associated with abnormal actin cytoskeleton remodeling as well as regulatory T cell phenotype, culminating in immune dysregulation and severe early-onset autoimmunity.
- 18 July 2025
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 17 (2) , 170-181
Open AccessA novel X-linked immune-mediated actinopathy in a boy with anti-NMDA receptor encephalitis and variant in DOCK11 gene
Pediatric encephalitis is a group of diseases characterized by brain disease, fever, seizures, cerebrospinal fluid pleocytosis and neuroradiological changes. Dedicator of cytokinesis proteins (DOCK) family proteins are of primary importance in actin cytoskeleton regulation. DOCK11 plays a crucial role in human immune diseases. In this paper, we describe a clinical case of anti-N-methyl-D-aspartate receptor encephalitis in a boy with a hemizygous variant in DOCK11 gene. DOCK11 deficiency is a new X-linked immunerelated actinopathy leading to impaired cell division cycle 42 (CDC42) activity and signal transducer and activator of transcription 5 (STAT5) activation. It is associated with abnormal actin cytoskeleton remodeling as well as regulatory T cell phenotype, culminating in immune dysregulation and severe early-onset autoimmunity.
- 27 April 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (2/2) , 74-81
Personalized genetic diagnosis of hereditary neurological diseases
Personalized medicine is methods for preventing of pathological conditions, diagnosing and treating based on the individual characteristics of the patient. Prevention of hereditary and congenital pathologies is the main goal of institutions and departments of medical genetic services. The need for genetic testing of children with congenital and hereditary diseases is 25,3%. The diversity of hereditary diseases was established based on the results of the study and analysis. The capabilities of the genetic laboratory are shown and the use of methods of molecular genetic diagnosis in children is scientifically justified. It has been shown that confirmation of more than 50% of genetic diseases by molecular genetic methods makes possibility to implement genotype-phenotype correlations and plan further medical observation of the child. The clinical effectiveness of whole exome sequencing to establish molecular diagnosis of hereditary and congenital pathologies was 73,3%. As part of the implementation of the strategy for the development of molecular genetic diagnostics, the spectrum of identified nucleotide sequence variants in genes responsible for hereditary and congenital pathologies was analyzed. Based on the obtained data and identified options, recommendations were given to doctors on the effectiveness of treatment, and individual rehabilitation programs were developed, in some cases excluding surgical correction of the defect in patients with movement disorders.
- 27 April 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (2/2) , 74-81
Personalized genetic diagnosis of hereditary neurological diseases
Personalized medicine is methods for preventing of pathological conditions, diagnosing and treating based on the individual characteristics of the patient. Prevention of hereditary and congenital pathologies is the main goal of institutions and departments of medical genetic services. The need for genetic testing of children with congenital and hereditary diseases is 25,3%. The diversity of hereditary diseases was established based on the results of the study and analysis. The capabilities of the genetic laboratory are shown and the use of methods of molecular genetic diagnosis in children is scientifically justified. It has been shown that confirmation of more than 50% of genetic diseases by molecular genetic methods makes possibility to implement genotype-phenotype correlations and plan further medical observation of the child. The clinical effectiveness of whole exome sequencing to establish molecular diagnosis of hereditary and congenital pathologies was 73,3%. As part of the implementation of the strategy for the development of molecular genetic diagnostics, the spectrum of identified nucleotide sequence variants in genes responsible for hereditary and congenital pathologies was analyzed. Based on the obtained data and identified options, recommendations were given to doctors on the effectiveness of treatment, and individual rehabilitation programs were developed, in some cases excluding surgical correction of the defect in patients with movement disorders.
- 1 January 2025
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 23 (5)
Early manifestations of combined mutations in the PACS1 and HFS4 genes in a newborn with Schuurs-Hoeijmakers syndrome
Schuurs-Hoeijmakers syndrome (OMIM: 615009), or PACS1 neurodevelopmental disorder (PACS1-NDD), is a rare autosomal dominant disease caused by a mutation in the PACS1 gene, characterized by intellectual disability and distinctive facial dysmorphism. The literature describes approximately 65 patients with Schuurs-Hoeijmakers syndrome aged 2 to 21 years. In current medicine, there is very little information about the features of Schuurs-Hoeijmakers syndrome in the neonatal period, as well as other manifestations when several significant mutations are detected. This article presents a clinical case of Schuurs-Hoeijmakers syndrome diagnosed in early childhood in a patient with combined mutations in the PACS1 and HFS4 genes. Key words: Schuurs-Hoeijmakers syndrome, PACS1 protein, HSF4 gene mutation, congenital cataract, hypotonia, coloboma, congenital heart defect
- 1 January 2025
- Published by Dynasty Publishing House in Voprosy detskoj dietologii
- Vol. 23 (5)
Early manifestations of combined mutations in the PACS1 and HFS4 genes in a newborn with Schuurs-Hoeijmakers syndrome
Schuurs-Hoeijmakers syndrome (OMIM: 615009), or PACS1 neurodevelopmental disorder (PACS1-NDD), is a rare autosomal dominant disease caused by a mutation in the PACS1 gene, characterized by intellectual disability and distinctive facial dysmorphism. The literature describes approximately 65 patients with Schuurs-Hoeijmakers syndrome aged 2 to 21 years. In current medicine, there is very little information about the features of Schuurs-Hoeijmakers syndrome in the neonatal period, as well as other manifestations when several significant mutations are detected. This article presents a clinical case of Schuurs-Hoeijmakers syndrome diagnosed in early childhood in a patient with combined mutations in the PACS1 and HFS4 genes. Key words: Schuurs-Hoeijmakers syndrome, PACS1 protein, HSF4 gene mutation, congenital cataract, hypotonia, coloboma, congenital heart defect
- Open Access
- 31 July 2024
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 5 (2) , 90-98
Whole-exome sequencing is the molecular-genetic test of the first-line in developmental and epileptic encephalopathies
Introduction. Developmental and epileptic encephalopathy are severe developmental disorders of the nervous system, characterized by recurrent epileptic seizures that begin over the neonatal period or childhood, accompanied by psychomotor retardation and intellectual disability. Massively parallel sequencing is a technology used to determine the complete nucleotide sequence of DNA or RNA. The technology is characterized by the high productivity and speed, marking the beginning of the golden age of genetics, allowing large volumes of DNA to be sequenced quickly and efficiently at lower costs. The aim of this study is to evaluate the effectiveness of whole- exome sequencing as a first-line genetic test in patients with developmental and epileptic encephalopathy and detect the structure of identified variants in the Russian population. Materials and methods. Patients with drug-resistant seizures, onset in neonatal and early childhood, hospitalized in the Psychoneurological Department during 2017–2023. All patients underwent clinical and genealogical analysis, video-EEG and MRI of the brain, and whole-exome sequencing. Results. The main result obtained in the study analysis of patients who underwent whole exome sequencing for the period of 2017-2023 was the detection rate of variants in genes associated with developmental and epileptic encephalopathy (21.7%; 71/331). Of these, 35/71 (49.3%) had pathogenic and probably pathogenic variants of the nucleotide sequence. Based on the results of whole exome sequencing patients were selected for the most effective targeted antiepileptic drugs. Conclusion. The use of whole-exome sequencing as a first-line molecular genetic test in patients with developmental and epileptic encephalopathy has been shown to be highly effective. Making an accurate genetic diagnosis is a fundamental background for precision therapy. Personalized medicine, that is, the attempt to personalize prevention, diagnosis, and treatment as much as possible according to the characteristics and needs of the patient, should be the main goal of clinical research and a new direction of modern medicine.
- 31 July 2024
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 5 (2) , 90-98
Open AccessWhole-exome sequencing is the molecular-genetic test of the first-line in developmental and epileptic encephalopathies
Introduction. Developmental and epileptic encephalopathy are severe developmental disorders of the nervous system, characterized by recurrent epileptic seizures that begin over the neonatal period or childhood, accompanied by psychomotor retardation and intellectual disability. Massively parallel sequencing is a technology used to determine the complete nucleotide sequence of DNA or RNA. The technology is characterized by the high productivity and speed, marking the beginning of the golden age of genetics, allowing large volumes of DNA to be sequenced quickly and efficiently at lower costs. The aim of this study is to evaluate the effectiveness of whole- exome sequencing as a first-line genetic test in patients with developmental and epileptic encephalopathy and detect the structure of identified variants in the Russian population. Materials and methods. Patients with drug-resistant seizures, onset in neonatal and early childhood, hospitalized in the Psychoneurological Department during 2017–2023. All patients underwent clinical and genealogical analysis, video-EEG and MRI of the brain, and whole-exome sequencing. Results. The main result obtained in the study analysis of patients who underwent whole exome sequencing for the period of 2017-2023 was the detection rate of variants in genes associated with developmental and epileptic encephalopathy (21.7%; 71/331). Of these, 35/71 (49.3%) had pathogenic and probably pathogenic variants of the nucleotide sequence. Based on the results of whole exome sequencing patients were selected for the most effective targeted antiepileptic drugs. Conclusion. The use of whole-exome sequencing as a first-line molecular genetic test in patients with developmental and epileptic encephalopathy has been shown to be highly effective. Making an accurate genetic diagnosis is a fundamental background for precision therapy. Personalized medicine, that is, the attempt to personalize prevention, diagnosis, and treatment as much as possible according to the characteristics and needs of the patient, should be the main goal of clinical research and a new direction of modern medicine.
- Open Access
- 30 June 2024
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 16 (2) , 120-129
A rare genetic Schuurs-Hoeijmakers syndrome (PACS1 syndrome)
PACS1 neurodevelopmental disorder (Schuurs-Hoeijmakers syndrome; MIM #615009) is a rare autosomal dominant genetic syndrome characterized by developmental delay, intellectual disability, dysmorphic features, and rare seizures. The article describes a clinical case of PACS1 syndrome in a female patient with developmental delay, speech disorder, motor development delay and epilepsy coupled to described variants in PACS1 gene (rs398123009, chr11:6621120, c.607C>T, p.Arg203Trp). Knowing PACS1 syndrome molecular mechanisms is important not only for genotype-phenotypic correlation, but also for developing new therapeutic approaches that could improve the quality of patients’ life.
- 30 June 2024
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 16 (2) , 120-129
Open AccessA rare genetic Schuurs-Hoeijmakers syndrome (PACS1 syndrome)
PACS1 neurodevelopmental disorder (Schuurs-Hoeijmakers syndrome; MIM #615009) is a rare autosomal dominant genetic syndrome characterized by developmental delay, intellectual disability, dysmorphic features, and rare seizures. The article describes a clinical case of PACS1 syndrome in a female patient with developmental delay, speech disorder, motor development delay and epilepsy coupled to described variants in PACS1 gene (rs398123009, chr11:6621120, c.607C>T, p.Arg203Trp). Knowing PACS1 syndrome molecular mechanisms is important not only for genotype-phenotypic correlation, but also for developing new therapeutic approaches that could improve the quality of patients’ life.
- Open Access
- 16 April 2024
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 16 (1) , 45-53
SEMA6B-related progressive myoclonus epilepsy in a patient with Klinefelter syndrome
In most cases, variants of nucleotide sequence in the SEMA6B gene account for developing the phenotype of progressive myoclonus epilepsy and, to a lesser extent, developmental encephalopathy with or without epilepsy. Loss-of-function variants in nucleotide sequence localized mainly in exon 17 of the SEMA6B gene contribute to production of aberrant proteins with “toxic” functions. A clinical case of status epilepsy in a patient with a variant in the SEMA6B gene (c.2506delС; p.His836ThrfsTer136; NM_032108.4) is described in the article that expands our knowledge regarding the SEMA6B gene variants resulting in progressive myoclonus epilepsy.
- 16 April 2024
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 16 (1) , 45-53
Open AccessSEMA6B-related progressive myoclonus epilepsy in a patient with Klinefelter syndrome
In most cases, variants of nucleotide sequence in the SEMA6B gene account for developing the phenotype of progressive myoclonus epilepsy and, to a lesser extent, developmental encephalopathy with or without epilepsy. Loss-of-function variants in nucleotide sequence localized mainly in exon 17 of the SEMA6B gene contribute to production of aberrant proteins with “toxic” functions. A clinical case of status epilepsy in a patient with a variant in the SEMA6B gene (c.2506delС; p.His836ThrfsTer136; NM_032108.4) is described in the article that expands our knowledge regarding the SEMA6B gene variants resulting in progressive myoclonus epilepsy.
- 12 April 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (2)
STRUCTURE OF HEREDITARY AND CONGENITAL PATHOLOGY IN A MULTIDISCIPLINARY SPECIALIZED PEDIATRIC CLINIC: PERSONALIZED APPROACH TO DIAGNOSTICS
Hereditary and congenital pathologies make up a significant proportion in the structure of the general morbidity and mortality of the child population. In this regard, the problem of personalized medical care in multidisciplinary clinical centers seems very urgent. In the Scientific-Practical Center of specialized medical care for children the medical genetic service successfully functions since 1995. In 2017–2019, patients were consulted by geneticists, which accounted for 10,6% of all discharged patients; karyotype studies were performed in 463 (20,4%) consulted patients, chromosomal pathology was revealed in 28 (6,04%) of all karyotyped patients. DNA research was performed in 188 patients: exome sequencing – in 112; sequencing of exons of the SCN1A gene – in 39; search for mutations in the PHOX2B gene – in 17; search for frequent mutations in the FGFR1,2,3 genes – in 15 (the technique was introduced since September 2018); sequencing of SLC2A1 gene – in 5 patients. The high demand for medical genetic counseling and laboratory genetic diagnosis of hereditary and congenital diseases confirms the need for independent medical genetic units in multidisciplinary clinical hospitals, that should interact with medical genetic services at regional and federal levels.
- 12 April 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (2)
STRUCTURE OF HEREDITARY AND CONGENITAL PATHOLOGY IN A MULTIDISCIPLINARY SPECIALIZED PEDIATRIC CLINIC: PERSONALIZED APPROACH TO DIAGNOSTICS
Hereditary and congenital pathologies make up a significant proportion in the structure of the general morbidity and mortality of the child population. In this regard, the problem of personalized medical care in multidisciplinary clinical centers seems very urgent. In the Scientific-Practical Center of specialized medical care for children the medical genetic service successfully functions since 1995. In 2017–2019, patients were consulted by geneticists, which accounted for 10,6% of all discharged patients; karyotype studies were performed in 463 (20,4%) consulted patients, chromosomal pathology was revealed in 28 (6,04%) of all karyotyped patients. DNA research was performed in 188 patients: exome sequencing – in 112; sequencing of exons of the SCN1A gene – in 39; search for mutations in the PHOX2B gene – in 17; search for frequent mutations in the FGFR1,2,3 genes – in 15 (the technique was introduced since September 2018); sequencing of SLC2A1 gene – in 5 patients. The high demand for medical genetic counseling and laboratory genetic diagnosis of hereditary and congenital diseases confirms the need for independent medical genetic units in multidisciplinary clinical hospitals, that should interact with medical genetic services at regional and federal levels.